Ahmed Elsada1, Amanda I Adler2. Show Affiliations » 1. National Institute for Health and Care Excellence, London SW1A 2BU, UK. Electronic address: ahmed.elsada@nice.org.uk. 2. National Institute for Health and Care Excellence, London SW1A 2BU, UK.
Abstract
Entities: Chemical Disease
Mesh： See more » Anilides/adverse effectsAnilides/economicsAnilides/therapeutic useAntineoplastic Agents/adverse effectsAntineoplastic Agents/economicsAntineoplastic Agents/therapeutic useCarcinoma, Renal Cell/drug therapyCarcinoma, Renal Cell/economicsCarcinoma, Renal Cell/enzymologyCarcinoma, Renal Cell/mortalityCost-Benefit AnalysisDisease-Free SurvivalDrug CostsHumansKidney Neoplasms/drug therapyKidney Neoplasms/economicsKidney Neoplasms/enzymologyKidney Neoplasms/mortalityPractice Guidelines as Topic/standardsProtein Kinase Inhibitors/adverse effectsProtein Kinase Inhibitors/economicsProtein Kinase Inhibitors/therapeutic usePyridines/adverse effectsPyridines/economicsPyridines/therapeutic useState Medicine/economicsState Medicine/standardsTreatment OutcomeUnited Kingdom
Substances： See more » AnilidesAntineoplastic AgentsProtein Kinase InhibitorsPyridinescabozantinib
Year: 2017 PMID： 28800862 DOI： 10.1016/S1470-2045(17)30590-9
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316